Novo Holdings, Glenview Capital and b2venture led the Series E round, which will fund commercial expansion in the US.
"Our commitment to delivering innovative solutions for acute care has never been stronger. This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position."
The capital injection will accelerate the silicon roadmap for minimally invasive neural implant applications.
"Our semiconductor-based approach is fundamentally reshaping what neural implants can achieve. By offering a customisable, compact solution that integrates seamlessly into medical devices, we’re empowering a new era of neural interfaces that are not only more powerful but also less invasive. This marks a transformative shift in neurological care."
The Newcastle based healthcare startup has raised £600k from regional investors to pilot its predictive software in Welsh hospitals.
"During my career as an orthopaedic surgeon, I’ve identified an opportunity for the pathway from patient referral to surgery to be improved through technology. With the length of waiting lists having only increased, the need to take advantage of this technology is as acute as ever."
The funding round was led by SFC Capital with additional support from Innovate UK.
"We’re excited to have led the investment into Reneural and to support the team on their journey to improve rehabilitation for stroke survivors. What really impressed us was their passion for tackling this problem, and we’re looking forward to seeing their impact on patient outcomes through their new VR products and mental health support."
The seed round was led by Fuel Ventures to support research and development and international expansion.
"I spent 14 years as a medical researcher, and I would spend hundreds of hours copying data from one system to another. The back-office process is completely broken. When you multiply this across the industry the costs for patients and research institutions are astronomical."